Striking study results last year indicated a new type of medicine may improve on Merck’s immunotherapy, spurring a wave of ...

programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer treatments. A checkpoint receptor that often resides on the surface of immune system cells, the PD-1 molecule ...

An early pilot trial suggests that combining atezolizumab (tecectriq) with rituximab (Rituxan), gemcitabine (gemzar) and ...

A 3-D image shows a T cell expressing the immune checkpoint receptor PD-1 (green) interacting with an antigen presenting cell expressing the ligand PD-L1 (magenta).

The keys to the lock are immune checkpoints such as programmed cell-death ligand 1 (PD-L1), and its receptor PD-1; discovering this system earned Nobel Prizes for James Allison, at the University ...

PD-L1 is a cell surface receptor expressed on both tumour and regulatory ... given as a monotherapy or in combination with MSD’s PD-1 inhibitor Keytruda (pembrolizumab), a widely-used treatment ...

and Palobiofarma’s adenosine A2A receptor inhibitor taminadenant (NIR178) in various cancer indications. With six PD-1/PD-L1 inhibitors on the market – and the most recent entrants struggling ...

DelveInsight's "BAVENCIO Market Size, Forecast, and Market Insight Report" highlights the details around BAVENCIO, a human ...

The following is a summary of “Efficacy and safety of PD-1/PD-L1 inhibitor monotherapy or combination therapy versus platinum-based chemotherapy as a first-line treatment of advanced urothelial cancer ...

Tharimmune (THAR) announced the expansion of its product pipeline with HS1940, a dual-target multispecific biologic engineered to bind to both ...

CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the first patient ...